UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 201

Sortiert nach

Can SGLT2 Inhibitor be Used for Diabetes Mellitus or Vascular Diseases?

Journal of Atherosclerosis and Thrombosis, 2020, Vol.27 (11), p.1139-1140

Takashi Nomiyama

2020

Link zum Volltext

Verfügbarkeit prüfen

Can SGLT2 Inhibitor be Used for Diabetes Mellitus or Vascular Diseases?

Journal of Atherosclerosis and Thrombosis, 2020/11/01, Vol.27(11), pp.1139-1140

Nomiyama, Takashi

2020

Link zum Volltext

Verfügbarkeit prüfen

SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation

Endocrine Journal, 2020, Vol.67(1), pp.99-106

2020

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4

Diabetes (New York, N.Y.), 2010-04, Vol.59 (4), p.1030-1037

2010

Link zum Volltext

Verfügbarkeit prüfen

GLP-1 Receptor Agonist Exendin-4 Attenuates NR4A Orphan Nuclear Receptor NOR1 Expression in Vascular Smooth Muscle Cells

Journal of Atherosclerosis and Thrombosis, 2019/02/01, Vol.26(2), pp.183-197

2019

Link zum Volltext

Verfügbarkeit prüfen

High sex hormone-binding globulin concentration is a risk factor for high fibrosis-4 index in middle-aged Japanese men

Endocrine Journal, 2019, Vol.66(7), pp.637-645

2019

Link zum Volltext

Verfügbarkeit prüfen

Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitro

Diabetology international, 2021-10, Vol.12 (4), p.389-398

2021

Link zum Volltext

Verfügbarkeit prüfen

Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial

Scientific reports, 2019-06, Vol.9 (1), p.8537, Article 8537

2019

Link zum Volltext

Verfügbarkeit prüfen

Anagliptin, a DPP-4 Inhibitor, Suppresses Proliferation of Vascular Smooth Muscles and Monocyte Inflammatory Reaction and Attenuates Atherosclerosis in Male apo E-Deficient Mice

Endocrinology (Philadelphia), 2013-03, Vol.154 (3), p.1260-1270

2013

Link zum Volltext

Verfügbarkeit prüfen

A simple questionnaire for the detection of testosterone deficiency in men with late-onset hypogonadism

Endocrine Journal, 2022, Vol.69(11), pp.1303-1312

2022

Link zum Volltext

Verfügbarkeit prüfen

Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth

Diabetes (New York, N.Y.), 2014-11, Vol.63 (11), p.3891-3905

2014

Link zum Volltext

Verfügbarkeit prüfen

Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy

Journal of Atherosclerosis and Thrombosis, 2022/01/01, Vol.29(1), pp.24-37

2022

Link zum Volltext

Verfügbarkeit prüfen

Prescription of oral hypoglycemic agents for patients with type 2 diabetes mellitus: A retrospective cohort study using a Japanese hospital database

Journal of diabetes investigation, 2017-03, Vol.8 (2), p.227-234

2017

Link zum Volltext

Verfügbarkeit prüfen

Augmented Growth Hormone Secretion and Stat3 Phosphorylation in an Aryl Hydrocarbon Receptor Interacting Protein (AIP)-Disrupted Somatotroph Cell Line

PloS one, 2016-10, Vol.11 (10), p.e0164131-e0164131

2016

Link zum Volltext

Verfügbarkeit prüfen

Total testosterone is the most valuable indicator of metabolic syndrome among various testosterone values in middle-aged Japanese men

Endocrine Journal, 2015, Vol.62(2), pp.123-132

2015

Link zum Volltext

Verfügbarkeit prüfen

Selective Androgen Receptor Modulator S42 Suppresses Prostate Cancer Cell Proliferation

Endocrinology (Philadelphia), 2018-04, Vol.159 (4), p.1774-1792

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of sodium–glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION)

Endocrine Journal, 2018, Vol.65(8), pp.859-867

2018

Link zum Volltext

Verfügbarkeit prüfen

Combined treatment with glucagon-like peptide-1 receptor agonist exendin-4 and metformin attenuates breast cancer growth

Diabetology international, 2022-07, Vol.13 (3), p.480-492

2022

Link zum Volltext

Verfügbarkeit prüfen

Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy

Cardiovascular diabetology, 2020-06, Vol.19 (1), p.1-89, Article 89

2020

Link zum Volltext

Verfügbarkeit prüfen

Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial

Cardiovascular diabetology, 2019-11, Vol.18 (1), p.158-158, Article 158

2019

Link zum Volltext

Verfügbarkeit prüfen

Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth

PloS one, 2015-10, Vol.10 (10), p.e0139709

2015

Link zum Volltext

Verfügbarkeit prüfen

Activation of overexpressed glucagon‐like peptide‐1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression

Journal of diabetes investigation, 2020-09, Vol.11 (5), p.1137-1149

2020

Link zum Volltext

Verfügbarkeit prüfen

Circular IRE-type RNAs of the NR5A1 gene are formed in adrenocortical cells

Biochemical and biophysical research communications, 2019-04, Vol.512 (1), p.1-6

2019

Link zum Volltext

Verfügbarkeit prüfen

Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice

Biochemistry and biophysics reports, 2019-07, Vol.18, p.100640-100640, Article 100640

2019

Link zum Volltext

Verfügbarkeit prüfen

Postpartum hypothalamic adrenal insufficiency with remission: A rare case

Endocrine Journal, 2017, Vol.64(2), pp.157-162

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 201

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(151)
Mit Volltextzugriff
(187)

Publikationsform

Artikel
(200)
Tagungsberichte
(1)

Sprache

Englisch
(163)
Japanisch
(79)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Can SGLT2 Inhibitor be Used for Diabetes Mellitus or Vascular Diseases?

Can SGLT2 Inhibitor be Used for Diabetes Mellitus or Vascular Diseases?

SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation

Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4

GLP-1 Receptor Agonist Exendin-4 Attenuates NR4A Orphan Nuclear Receptor NOR1 Expression in Vascular Smooth Muscle Cells

High sex hormone-binding globulin concentration is a risk factor for high fibrosis-4 index in middle-aged Japanese men

Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitro

Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial

Anagliptin, a DPP-4 Inhibitor, Suppresses Proliferation of Vascular Smooth Muscles and Monocyte Inflammatory Reaction and Attenuates Atherosclerosis in Male apo E-Deficient Mice

A simple questionnaire for the detection of testosterone deficiency in men with late-onset hypogonadism

Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth

Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy

Prescription of oral hypoglycemic agents for patients with type 2 diabetes mellitus: A retrospective cohort study using a Japanese hospital database

Augmented Growth Hormone Secretion and Stat3 Phosphorylation in an Aryl Hydrocarbon Receptor Interacting Protein (AIP)-Disrupted Somatotroph Cell Line

Total testosterone is the most valuable indicator of metabolic syndrome among various testosterone values in middle-aged Japanese men

Selective Androgen Receptor Modulator S42 Suppresses Prostate Cancer Cell Proliferation

Efficacy and safety of sodium–glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION)

Combined treatment with glucagon-like peptide-1 receptor agonist exendin-4 and metformin attenuates breast cancer growth

Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy

Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial

Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth

Activation of overexpressed glucagon‐like peptide‐1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression

Circular IRE-type RNAs of the NR5A1 gene are formed in adrenocortical cells

Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice

Postpartum hypothalamic adrenal insufficiency with remission: A rare case

Suchergebnisse filtern